JP2025511227A5 - - Google Patents

Info

Publication number
JP2025511227A5
JP2025511227A5 JP2024558105A JP2024558105A JP2025511227A5 JP 2025511227 A5 JP2025511227 A5 JP 2025511227A5 JP 2024558105 A JP2024558105 A JP 2024558105A JP 2024558105 A JP2024558105 A JP 2024558105A JP 2025511227 A5 JP2025511227 A5 JP 2025511227A5
Authority
JP
Japan
Prior art keywords
preparation according
nasal preparation
substituted
nasal
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024558105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/017126 external-priority patent/WO2023192602A2/en
Publication of JP2025511227A publication Critical patent/JP2025511227A/ja
Publication of JP2025511227A5 publication Critical patent/JP2025511227A5/ja
Pending legal-status Critical Current

Links

JP2024558105A 2022-04-01 2023-03-31 呼吸器刺激性経鼻製剤 Pending JP2025511227A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263326578P 2022-04-01 2022-04-01
US63/326,578 2022-04-01
PCT/US2023/017126 WO2023192602A2 (en) 2022-04-01 2023-03-31 Respiratory stimulant nasal formulations

Publications (2)

Publication Number Publication Date
JP2025511227A JP2025511227A (ja) 2025-04-15
JP2025511227A5 true JP2025511227A5 (https=) 2026-03-31

Family

ID=88195037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024558105A Pending JP2025511227A (ja) 2022-04-01 2023-03-31 呼吸器刺激性経鼻製剤

Country Status (10)

Country Link
US (1) US20230310440A1 (https=)
EP (1) EP4504206A4 (https=)
JP (1) JP2025511227A (https=)
KR (1) KR20240167901A (https=)
CN (1) CN119630402A (https=)
AU (1) AU2023241731A1 (https=)
CA (1) CA3247210A1 (https=)
MX (1) MX2024012104A (https=)
TW (1) TW202345837A (https=)
WO (1) WO2023192602A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤
US20230414624A1 (en) * 2022-06-24 2023-12-28 Enalare Therapeutics Inc. Methods of treating neurological ventilatory insufficiency
KR102882277B1 (ko) 2023-11-22 2025-11-06 헤일러코리아 주식회사 구분된 공간을 구비하는 교체형 카트리지 및 이를 포함하는 네블라이징 디바이스
KR102908992B1 (ko) 2023-11-22 2026-01-14 박세진 네블라이징 디바이스용 교체형 카트리지

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20050053659A1 (en) * 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
AU2011336764B2 (en) * 2010-11-29 2017-02-23 Galleon Pharmaceuticals, Inc. Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
SG11201407964YA (en) * 2012-05-29 2014-12-30 Galleon Pharmaceuticals Inc Novel compounds and compositions for treatment of breathing control disorders or diseases
US11903951B2 (en) * 2016-06-03 2024-02-20 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2019182745A1 (en) * 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CA3141612A1 (en) * 2019-05-22 2020-11-26 Enalare Therapeutics Inc. Methods and pharmaceutical compositions to treat drug overdose
CA3236586A1 (en) * 2021-11-02 2023-05-11 Joseph Pergolizzi Methods of treating respiratory depression modulated by a non-opioid agent
JP2025511227A (ja) * 2022-04-01 2025-04-15 エナラーレ セラピューティクス インコーポレイテッド 呼吸器刺激性経鼻製剤

Similar Documents

Publication Publication Date Title
JP2025511227A5 (https=)
US12383528B2 (en) Cromolyn esters and uses thereof
JP4334620B2 (ja) ヒアルロン酸の局所麻酔剤との塩からなる医薬品
AU2005228685B2 (en) Hydrazide-containing CFTR inhibitor compounds and uses thereof
JP2022000482A5 (https=)
US10675353B2 (en) Pegylated carfilzomib compounds
RU2219167C2 (ru) N-замещенные аминотетралины как лиганды для рецептора y5 нейропептида y, полезные при лечении ожирения и других расстройств
EP3463294B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide statistique
US12612391B2 (en) Cromolyn derivatives and uses thereof
JP2001278789A (ja) サリドマイドを有効成分とする医薬品製剤
WO2005011629A1 (en) Bioactive compositions comprising triazines
RU2361593C3 (ru) Комбинация азеластина и стероидов
JP2012001558A (ja) ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
US11241502B2 (en) Stable compositions of pegylated carfilzomib compounds
JPH06505265A (ja) ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体
JPWO2017104725A1 (ja) 創傷治療剤
JP2014502267A (ja) 炎症及び血管増殖に関連する眼疾患の治療法
JP2025501169A5 (https=)
CN107987033A (zh) 香草醛及其异构体在制备na抑制剂中的应用
US6054462A (en) Intranasal antimigraine compositions
JP2025510725A5 (https=)
JP2023538449A5 (https=)
RU2002113657A (ru) Пролекарства 6-метокси-2-нафтилуксусной кислоты
HRP20100301T1 (hr) Ciklopeptidni derivati sa anti-integrinskom aktivnošću
CN113214414A (zh) 改性聚乙烯醇、聚乙烯醇微纳凝胶的可控制备方法及应用